What is the nature of the additional share grant to Jeffrey Yu at OneMedNet (ONMD)?

The additional 219,429 OneMedNet common shares were issued to Jeffrey Yu in lieu of prior cash compensation owed. These shares were valued at the same 10-day volume-weighted average price of $0.83 per share immediately before the April 1, 2026 issuance date.

OneMedNet (ONMD) CMO Jeffrey Yu invests $750k and takes equity in lieu of cash

Filing Impact

(Very High)

Filing Sentiment

(Positive)

Form Type

Rhea-AI Filing Summary

OneMedNet Corp director and Chief Medical Officer Jeffrey Yu increased his stake through a sizable cash investment and share grant. On April 1, 2026, he invested $750,000 in a subscription agreement, receiving 903,614 common shares at $0.83 each, and was issued 219,429 shares in lieu of prior cash compensation at the same price. Following these transactions, he directly owns 8,229,837 common shares. An additional 1,311,970 shares are held in a trust with an independent trustee, for which he disclaims beneficial ownership.

Insights

Yu commits $750,000 and takes more equity instead of cash pay.

Chief Medical Officer and director Jeffrey Yu, also a more than 10% owner, entered a subscription agreement on April 1, 2026 to invest $750,000 in OneMedNet Corp. He received 903,614 common shares at $0.83 per share, based on the 10‑day volume‑weighted average price.

On the same date, he was granted 219,429 additional common shares, issued in lieu of prior cash compensation owed, also valued using the 10‑day volume‑weighted average price. These are compensation-related and not open‑market trades.

After these transactions, Yu directly holds 8,229,837 common shares. A further 1,311,970 shares are held by a trust with an independent trustee; he has no investment control and disclaims beneficial ownership of those trust shares.

Insider Trade Summary

Net Buyer: 903,614 shares ($750,000)

Net Buy 3 txns

Insider Yu Jeffrey

Role Chief Medical Officer

Bought 903,614 shs ($750K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	903,614	$0.83	$750K
Grant/Award	Common Stock	219,429	$0.83	$182K
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 8,229,837 shares (Direct, null); Common Stock — 1,311,970 shares (Indirect, By trust for children)

Footnotes (1)

On April 1, 2026, the issuer entered into a subscription agreement with the reporting person for a $750,000 investment in the issuer. The shares were valued at the volume-weighted average price for the 10 trading days immediately prior to the purchase date. Represents shares issued in lieu of prior cash compensation owed to the reporting person. The shares were valued at the volume-weighted average price for the 10 trading days immediately prior to the issuance date. The shares are held by trust with an independent trustee, in which the reporting person has no investment control. The reporting person disclaims beneficial ownership of these shares, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the shares for purposes of Section 16 or for any other purpose.

Key Figures

Subscription investment: $750,000 Subscription shares: 903,614 shares at $0.83 Compensation shares: 219,429 shares at $0.83 +3 more

6 metrics

Subscription investment $750,000 Cash invested by Jeffrey Yu on April 1, 2026

Subscription shares 903,614 shares at $0.83 Common stock issued for $750,000 investment

Compensation shares 219,429 shares at $0.83 Issued in lieu of prior cash compensation

Direct holdings after 8,229,837 shares Jeffrey Yu’s direct common stock position after transactions

Trust-held shares 1,311,970 shares Held in children’s trust with independent trustee; Yu disclaims ownership

VWAP lookback period 10 trading days Period used to determine share valuation for investment and compensation

Key Terms

subscription agreement, volume-weighted average price, in lieu of prior cash compensation, independent trustee, +2 more

6 terms

subscription agreement financial

"entered into a subscription agreement with the reporting person for a $750,000 investment"

A subscription agreement is a legal contract in which an investor agrees to buy a specific number of a company’s shares or other securities under set terms, including price, payment method and conditions for closing the sale. It matters to investors because it legally locks in their purchase and the company’s obligations, determines ownership percentage and any investor rights, and can include conditions or promises that affect future control or returns—like signing a detailed purchase order for equity.

volume-weighted average price financial

"valued at the volume-weighted average price for the 10 trading days"

Volume-weighted average price (VWAP) is the average price of a stock over a specific time period where each trade is weighted by the number of shares traded, so larger trades influence the average more than small ones. Investors and traders use VWAP as a reference point to judge whether trades are happening at relatively good or poor prices—like checking the average price paid for an item at a market where bulk purchases count more than single-item buys.

in lieu of prior cash compensation financial

"Represents shares issued in lieu of prior cash compensation owed"

independent trustee regulatory

"held by trust with an independent trustee, in which the reporting person has no investment control"

disclaims beneficial ownership regulatory

"The reporting person disclaims beneficial ownership of these shares"

Section 16 regulatory

"beneficial owner of the shares for purposes of Section 16 or for any other purpose"

Section 16 is a U.S. securities law rule that governs the trading and disclosure obligations of company insiders — typically officers, directors and large shareholders — to promote transparency and deter unfair profit-taking. It requires insiders to publicly report their stock trades and allows companies or the issuer to reclaim quick, short-term profits from certain insider trades, like a scoreboard and a refund policy that help investors see and limit possible insider advantage.

Form 4 Insider Transactions: What Each Field Means →

04/24/2026 - 08:40 AM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Yu Jeffrey

(Last)

(First)

(Middle)

6385 OLD SHADY OAK ROAD, SUITE 250

(Street)

EDEN PRAIRIE

MINNESOTA

55344

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
OneMedNet Corp [ ONMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	X	10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	04/01/2026		P⁽¹⁾		903,614	A	$0.83	8,229,837	D
Common Stock	04/01/2026		A⁽²⁾		219,429	A	$0.83	8,449,266	D
Common Stock								1,311,970	I	By trust for children⁽³⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. On April 1, 2026, the issuer entered into a subscription agreement with the reporting person for a $750,000 investment in the issuer. The shares were valued at the volume-weighted average price for the 10 trading days immediately prior to the purchase date.

2. Represents shares issued in lieu of prior cash compensation owed to the reporting person. The shares were valued at the volume-weighted average price for the 10 trading days immediately prior to the issuance date.

3. The shares are held by trust with an independent trustee, in which the reporting person has no investment control. The reporting person disclaims beneficial ownership of these shares, and this report shall not be deemed an admission that the reporting person is the beneficial owner of the shares for purposes of Section 16 or for any other purpose.

	/s/ Robert Golden, Attorney-in-Fact	04/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did OneMedNet (ONMD) report for Jeffrey Yu?

Jeffrey Yu reported a subscription investment and a share grant. He received 903,614 shares for a $750,000 cash investment and 219,429 shares issued instead of prior cash compensation, all at $0.83 per share, increasing his direct common stock holdings.

How much did Jeffrey Yu invest in OneMedNet (ONMD) and at what price?

Jeffrey Yu invested $750,000 in OneMedNet through a subscription agreement. The company valued the 903,614 shares he received using the volume-weighted average trading price of $0.83 over the 10 days immediately before the April 1, 2026 purchase date.

How many OneMedNet (ONMD) shares does Jeffrey Yu own after these transactions?

After the April 1, 2026 transactions, Jeffrey Yu directly owns 8,229,837 shares of OneMedNet common stock. In addition, a trust for his children holds 1,311,970 shares, but he has no investment control over that trust and disclaims beneficial ownership of those shares.

Were any of Jeffrey Yu’s OneMedNet (ONMD) shares bought on the open market?

The filing describes 903,614 shares as a purchase but clarifies in a footnote that they were issued under a subscription agreement for a $750,000 investment. The price was set using the 10-day volume-weighted average trading price rather than ordinary open-market buying.

How are the trust-held OneMedNet (ONMD) shares attributed to Jeffrey Yu?

A trust for Jeffrey Yu’s children holds 1,311,970 OneMedNet shares with an independent trustee. The filing states Yu has no investment control over these shares and expressly disclaims beneficial ownership for Section 16 and any other legal purpose.